Show simple item record

dc.contributor.advisorFielding, B.C
dc.contributor.authorSmith, Marjorie
dc.date.accessioned2018-07-25T10:47:18Z
dc.date.available2018-08-31T22:10:06Z
dc.date.issued2017
dc.identifier.urihttp://hdl.handle.net/11394/6111
dc.descriptionMagister Scientiae - MSc (Medical BioSciences)
dc.description.abstractCoronaviruses (CoVs) are enveloped viruses composed of single-stranded, positive sense RNA viruses with the largest viral genomes among RNA viruses (27-33 kb). In 2004, human coronavirus NL63 (HCoV-NL63) was discovered by researchers from The Netherlands. Since its discovery, it has been found in countries all over the world and affects mainly young children between ages 0-5 years old, immunocompromised and elderly people. HCoV-NL63 has been indicated to cause both mild upper and more serious, but less common, lower respiratory tract infections and are commonly associated with other respiratory viruses in co-infections that can increase the severity of HCoV-NL63 infection. The nucleocapsid (N) protein of HCoV-NL63 is a multifunctional phosphoprotein that modulates the assembly of the ribonucleocapsid core of mature virions. During infection, the N protein is expressed at high levels within an infected cell and elicits a strong immune response in infected patients. For this reason, N protein was used to generate antibodies against an immune response to the presence of HCoV-NL63 N protein in mouse blood serum.
dc.language.isoen
dc.publisherUniversity of the Western Cape
dc.titleThe Generation of Antibodies against Human Coronavirus NL63 (HCoV-NL63) Nucleocapsid Protein
dc.rights.holderUniversity of the Western Cape


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record